This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.
Xeljanz is approved in the US for use in adults with rheumatoid arthritis (RA) who have not responded well to methotrexate treatment. ... It is also approved to treat patients with psoriatic arthritis who have not responded well to prior methotrexate
It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as studies in psoriatic arthritis and atopic dermatitis ... Novartis’ drug is currently approved for adults with
J&J is already a leader in the immunology market, and recently filed its next-generation IL-23 inhibitor Tremfya in psoriatic arthritis (PsA) with the European Medicines Agency.
Otezla grew 26% to reach $1.6bn in sales across its psoriasis, psoriatic arthritis and Behçet's disease indications last year, and has continued its expansion this year with a tally
Narrowly missed statistical significance for superiority. Novartis’ Cosentyx (secukinumab) failed to show significant superiority over AbbVie’s Humira (adalimumab) in a head-to-head trial in psoriatic arthritis (PsA). ... We will assess the EXCEED
Aside from its oncology business, Pfizer also saw growth of its global revenues for Xeljanz to $599m due to continued volume growth in the rheumatoid arthritis indication and the recent launch ... for psoriatic arthritis in the US.
More from news
Approximately 15 fully matching, plus 121 partially matching documents found.
For example, when developing a patient support programme for patients with Ankylosing Spondylitis and Psoriatic Arthritis, earthware identified that, for newly diagnosed patients, the impact of receiving the diagnosis on their
Putting it into practice. This process is well illustrated through our development of Psoriasis360.co.uk, a website to support people with psoriatic disease. ... We have also been continuously developing new content based on patients’ needs: an
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular
Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Millefeuille’ [ IMDB] explores the issues of isolation and restriction people with psoriasis and psoriatic arthritis struggle with, and the degree to which they are self-imposed, through the character of Élodie –
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles
More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...